Breast Most cancers Affiliation Consortium. Breast most cancers threat genes—Affiliation evaluation in additional than 113,000 girls. N. EngI. J. 384, 428–439 (2021).
Korde, L. A., Somerfield, M. R. & Hershman, D. L. Use of immune checkpoint inhibitor pembrolizumab within the remedy of high-risk, early-stage triple-negative breast most cancers: ASCO guideline speedy advice replace. JCO 40, 1696–1698 (2022).
Moy, B., Rumble, R. B. & Carey, L. A. Chemotherapy and focused remedy for endocrine-pretreated or hormone receptor-negative metastatic breast most cancers: ASCO guideline speedy advice replace. JCO 41, 1318–1320 (2023).
Rizzo, A., Cusmai, A., Acquafredda, S., Rinaldi, L. & Palmiotti, G. Ladiratuzumab vedotin for metastatic triple damaging most cancers: Preliminary outcomes, key challenges, and medical potential. Skilled Opin. Investig. Medicine 31, 495–498 (2022).
Guven, D. C. et al. The affiliation between albumin ranges and survival in sufferers handled with immune checkpoint inhibitors: A scientific evaluate and meta-analysis. Entrance. Mol. Biosci. 9, 2296–2889 (2022).
Rizzo, A. et al. Hypertransaminasemia in most cancers sufferers receiving immunotherapy and immune-based combos: The MOUSEION-05 research. Most cancers Immunol. Immunother. 72, 1381–1394 (2023).
Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast most cancers. N. EngI. J. 363, 1938–1948 (2010).
Li, S. D. & Huang, L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 5, 496–504 (2008).
Bertrand, N., Wu, J., Xu, X. Y., Kamaly, N. & Farokhzad, O. C. Most cancers nanotechnology: The affect of passive and lively focusing on within the period of recent most cancers biology. Adv. Drug Deliv. Rev. 66, 2–25 (2014).
Shi, J. J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Most cancers nanomedicine: Progress, challenges and alternatives. Nat. Rev. Most cancers 17, 20–37 (2017).
Zhu, G. H., Grey, A. B. C. & Patra, H. Ok. Nanomedicine: Controlling nanoparticle clearance for translational success. Tendencies Pharmacol. Sci. 43, 709–711 (2022).
Mosleh-Shirazi, S., Abbasi, M., Shafiee, M., Kasaee, S. R. & Amani, A. M. Renal clearable nanoparticles: An increasing horizon for enhancing biomedical imaging and most cancers remedy. Mater. In the present day Commun. 26, 102064 (2021).
Xu, M. et al. Dimension-dependent in vivo transport of nanoparticles: Implications for supply, focusing on, and clearance. ACS Nano 17, 20825–20849 (2023).
Bayda, S., Adeel, M., Tuccinardi, T., Cordani, M. & Rizzolio, F. The historical past of nanoscience and nanotechnology: From chemical-physical functions to nanomedicine. Molecules 25, 112 (2020).
Rennick, J. J., Johnston, A. P. R. & Parton, R. G. Key rules and strategies for learning the endocytosis of organic and nanoparticle therapeutics. Nat. Nanotechnol. 16, 266–276 (2021).
Harish, V. et al. Overview on nanoparticles and nanostructured supplies: Bioimaging, biosensing, drug supply, tissue engineering, antimicrobial, and agro-food functions. Nanomaterials 12, 457 (2022).
Ouyang, J. et al. Minimally invasive nanomedicine: Nanotechnology in photo-/ultrasound-/radiation-/magnetism-mediated remedy and imaging. Chem. Soc. Rev. 51, 4996–5041 (2022).
Li, T., Lu, X. M., Zhang, M. R., Hu, Ok. & Li, Z. Peptide-based nanomaterials: Self-assembly, properties and functions. Bioact. Mater. 11, 268–282 (2022).
Overchuk, M., Weersink, R. A., Wilson, B. C. & Zheng, G. Photodynamic and photothermal therapies: Synergy alternatives for nanomedicine. ACS Nano 17, 7979–8003 (2023).
Liu, S., Pan, X. T. & Liu, H. Y. Two-dimensional nanomaterials for photothermal remedy. Angew. Chem. Int. Ed. 59, 5890–5900 (2020).
Xu, C. et al. Metabolomics-derived biomarkers for biosafety evaluation of Gd-based nanoparticle magnetic resonance imaging distinction brokers. Analyst 149, 1169–1178 (2024).
Zhu, G. et al. Biosafety threat evaluation of gold and aluminum nanoparticles in tumor-bearing mice. APL Bioeng. 7, 016116 (2023).
Stack, T. et al. Enhancing subcutaneous injection and goal tissue accumulation of nanoparticles through co-administration with macropinocytosis inhibitory nanoparticles (MiNP). Nanoscale Horiz. 6, 393–400 (2021).
Mills, J. A., Liu, F. F., Jarrett, T. R., Fletcher, N. L. & Thurecht, Ok. J. Nanoparticle based mostly medicines: Approaches for evading and manipulating the mononuclear phagocyte system and potential for medical translation. Biomater. Sci. 10, 3029–3053 (2022).
Wang, L. et al. Exploring and analyzing the systemic supply obstacles for nanoparticles. Adv. Funct. Mater. 34, 2308446 (2023).
Souri, M. et al. In the direction of principled design of most cancers nanomedicine to speed up medical translation. Mater. In the present day Bio 13, 100208 (2022).
Gustafson, H. H., Holt-Casper, D., Grainger, D. W. & Ghandehari, H. Nanoparticle uptake: The phagocyte drawback. Nano In the present day 10, 487–510 (2015).
Verwilst, P., Park, S., Yoon, B. & Kim, J. S. Latest advances in Gd-chelate based mostly bimodal optical/MRI distinction brokers. Chem. Soc. Rev. 44, 1791–1806 (2015).
Botta, M. & Tei, L. Relaxivity enhancement in macromolecular and nanosized GdIII-based MRI distinction brokers. Eur. J. Inorg. Chem. 2012, 1945–1960 (2012).
Lee, G. H., Chang, Y. M. & Kim, T. J. Blood-pool and focusing on MRI distinction brokers: From Gd-chelates to Gd-nanoparticles. Eur. J. Inorg. Chem. 2012, 1924–1933 (2012).
Knopp, M. V., Tengg-Kobligk, H. V., Floemer, F. & Schoenberg, S. O. Distinction brokers for MRA: Future instructions. J. Magn. Reson. Imaging 10, 314–316 (1999).
Yue, H., Park, J. Y., Chang, Y. M. & Lee, G. H. Ultrasmall europium, gadolinium, and dysprosium oxide nanoparticles: Polyol synthesis, properties, and biomedical imaging functions. Mini Rev. Med. Chem. 20, 1767–1780 (2020).
Li, X. D., Solar, Y. H., Ma, L. N., Liu, G. F. & Wang, Z. X. The renal clearable magnetic resonance imaging distinction brokers: State-of-the-art and up to date advances. Molecules 25, 5072 (2020).
Liu, F. Y., He, X. X., Zhang, J. P., Zhang, H. M. & Wang, Z. X. Using tryptone as a common part switch agent to provide renal clearable nanodots for bioimaging. Small 11, 3676–3685 (2015).
Yan, Y. N. et al. Renal-clearable hyaluronic acid functionalized NaGdF4 nanodots with enhanced tumor accumulation. RSC Adv. 10, 13872–13878 (2020).
Kim, C. R. et al. Ligand-size dependent water proton relaxivities in ultrasmall gadolinium oxide nanoparticles and in vivo T1 MR photos in a 1.5 T MR discipline. Phys. Chem. Chem. Phys. 16, 19866–19873 (2014).
Ni, Ok. et al. Geometrically confined ultrasmall gadolinium oxide nanoparticles increase the T1 distinction potential. Nanoscale 8, 3768–3774 (2016).
Cheng, Z. L., Thorek, D. L. J. & Tsourkas, A. Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging distinction agent. Angew. Chem. Int. Ed. 49, 346–350 (2010).
Viger, M. L., Sankaranarayanan, J., Lux, C. D. G., Chan, M. & Almutairi, A. Collective activation of MRI brokers through encapsulation and disease-triggered releas. J. Am. Chem. Soc. 135, 7847–7850 (2013).
Wang, J. et al. Detection of kidney dysfunction by way of in vivo magnetic resonance imaging with renal-clearable gadolinium nanoprobes. Anal. Chem. 94, 4005–4011 (2022).
Chen, H. D., Li, X. D., Liu, F. Y., Zhang, H. M. & Wang, Z. X. Renal clearable peptide functionalized NaGdF4 nanodots for high-efficiency monitoring orthotopic colorectal tumor in mouse. Mol. Pharm. 14, 3134–3141 (2017).
Jiang, Z. L. et al. Boosting vascular imaging-performance and systemic biosafety of ultra-small NaGdF4 nanoparticles through floor engineering with rationally designed novel hydrophilic block co-polymer. Small Strategies 6, 2101145 (2022).
Xu, P. P. et al. Extremely-small albumin templated Gd/Ru composite nanodots for in vivo twin modal MR/thermal imaging guided photothermal remedy. Adv. Healthc. Mater. 7, 1800322 (2018).
Nkandeu, D. S. et al. The involvement of a chemokine receptor antagonist CTCE-9908 and kynurenine metabolites in most cancers improvement. Cell Biochem. Funct. 40, 608–622 (2022).
Buck, A. Ok. et al. CXCR4-targeted theranostics in oncology. Eur. J. Nucl. Med. Mol. Imaging 49, 4133–4144 (2022).
Zhao, H. L. et al. CXCR4 over-expression and survival in most cancers: A system evaluate and meta-analysis. Oncotarget 6, 5022–5040 (2014).
Lippitz, B. E. Cytokine patterns in sufferers with most cancers: A scientific evaluate. Lancet Oncol. 14, 218–228 (2013).
Tune, N. et al. Advance within the position of chemokines/chemokine receptors in carcinogenesis: Give attention to pancreatic most cancers. Eur. J. Pharmacol. 967, 176357 (2024).
Liu, G. F., Chen, H. D., Yu, S. N., Li, X. D. & Wang, Z. X. CXCR4 peptide conjugated Au–Fe2O3 Nanoparticles for tumor-targeting magnetic resonance imaging. Chem. Res. Chin. Univ. 34, 584–589 (2018).
Meng, Y. L. et al. CXC chemokine receptor kind 4 antagonistic gold nanorods induce particular immune responses and long-term immune reminiscence to fight triple-negative breast most cancers. ACS Appl. Mater. Interfaces 15, 18734–18746 (2023).
Fu, Y. et al. CXC chemokine receptor 4 antagonist functionalized renal clearable manganese-doped iron oxide nanoparticles for active-tumor-targeting magnetic resonance imaging-guided bio-photothermal remedy. ACS Appl. Bio Mater. 2, 3613–3621 (2019).
Bhattarai, S., Mackeyev, Y., Venkatesulu, B. P., Krishnanb, S. & Singh, P. Ok. CXC chemokine receptor 4 (CXCR4) focused gold nanoparticles potently improve radiotherapy outcomes in breast most cancers. Nanoscale 13, 19056–19065 (2021).
Yang, C. et al. Biomimetic nanovaccines potentiating dendritic cell internalization through CXCR4-mediated macropinocytosis. Adv. Healthc. Mater. 12, 2202064 (2023).
Johnson, N. J. J., Oakden, W., Stanisz, G. J., Prosser, R. S. & Veggel, F. C. J. M. V. Dimension-tunable, ultrasmall NaGdF4 nanoparticles: Insights into their T1 MRI distinction enhancement. Chem. Mater. 23, 3714–3722 (2011).
